430 related articles for article (PubMed ID: 18231953)
1. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
[TBL] [Abstract][Full Text] [Related]
2. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
Van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Hoffman R; Sossman J
Bone Marrow Transplant; 2003 Sep; 32(5):471-6. PubMed ID: 12942092
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
4. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience.
Gómez-Almaguer D; Ruiz-Argüelles GJ; Tarín-Arzaga Ldel C; González-Llano O; Jaime-Pérez JC; López-Martínez B; Cantú-Rodríguez OG; Herrera-Garza JL
Biol Blood Marrow Transplant; 2003 Mar; 9(3):157-61. PubMed ID: 12652465
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
7. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
[TBL] [Abstract][Full Text] [Related]
8. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
9. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Chen HY; Mahmud N; Quigley J; Hoffman R; Jessop E; Beri R; Rondelli D
Bone Marrow Transplant; 2006 Oct; 38(7):477-82. PubMed ID: 16980995
[TBL] [Abstract][Full Text] [Related]
10. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
[TBL] [Abstract][Full Text] [Related]
11. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
[TBL] [Abstract][Full Text] [Related]
12. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Claviez A; Klingebiel T; Beyer J; Nürnberger W; Ehninger G; Suttorp M; Dreger P; Dörffel W; Schmitz N
Ann Hematol; 2004 Apr; 83(4):237-41. PubMed ID: 14625790
[TBL] [Abstract][Full Text] [Related]
14. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
Steiner M; Matthes-Martin S; Attarbaschi A; Minkov M; Grois N; Unger E; Holter W; Vormoor J; Wawer A; Ouachee M; Woessmann W; Gadner H
Bone Marrow Transplant; 2005 Aug; 36(3):215-25. PubMed ID: 15937510
[TBL] [Abstract][Full Text] [Related]
15. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
16. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
[TBL] [Abstract][Full Text] [Related]
17. Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.
Yanagisawa R; Nakazawa Y; Sakashita K; Tanaka M; Shikama N; Kamijo T; Shiohara M; Koike K
Pediatr Transplant; 2009 Sep; 13(6):737-45. PubMed ID: 19207225
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
[TBL] [Abstract][Full Text] [Related]
19. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
20. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
